Pantoprazole intravenous administration

Pantoprazole is a substituted benzimidazole sulfoxide proton pump inhibitor (Fig. 11). Like other proton pump inhibitors such as lansoprazole, all chiral benzimidazoles are administered as racemic mixtures. Pantoprazole is metabolized to pantoprazole sulphone as a major metabolite, and pantoprazole sulfide as a minor metabolite (Fig. 11). The reoxidation of pantoprazole sulfide to pantoprazole occurs in vivo, resulting in chiral inversion of pantoprazole enantiomers. Significant chiral inversion occurred after intravenous and oral administration of (-F)-pantoprazole [139]. The mechanism of this inversion has not yet been identified. 

Pue MA, Laroche J, Meineke I, et al. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. EurJ Clin Pharmacol 1993 44 575-578. 

---